Associations with breast or ovarian cancer risk for loci previously reported to be associated with cancer risk for BRCA1 mutation carriers.


DOI:10.1371/journal.pgen.1003212.t001, Dimensions: dataset.8834958,


Dicks, Ed (2)



  1. (1) Mayo Clinic, grid.66875.3a
  2. (2) University of Cambridge, grid.5335.0
  3. (3) Erasmus MC, grid.5645.2
  4. (4) VU University Medical Center, grid.16872.3a
  5. (5) Queen's University Belfast, grid.4777.3
  6. (6) Liverpool Womens NHS Foundation Trust, grid.419317.9
  7. (7) Nottingham University Hospitals NHS Trust, grid.240404.6
  8. (8) University of Aberdeen, grid.7107.1
  9. (9) Aix-Marseille University, grid.5399.6
  10. (10) Pomeranian Medical University, grid.107950.a
  11. (11) University Hospital Schleswig-Holstein, grid.412468.d
  12. (12) Sheba Medical Center, grid.413795.d
  13. (13) Odense University Hospital, grid.7143.1, Southern Denmark Region
  14. (14) Memorial Sloan Kettering Cancer Center, grid.51462.34
  15. (15) Istituto Oncologico Veneto, grid.419546.b
  16. (16) National Institute of Oncology, grid.419617.c
  17. (17) University of California, San Francisco, grid.266102.1
  18. (18) Centre Hospitalier Universitaire de Québec, grid.411081.d


Freq = frequency of allele 2 in unaffected BRCA1 carriers.HR = Per allele Hazard Ratio associated with allele 2, under a single disease risk model, unless specified.r2: correlation between the SNP in the present study and the published SNP.*SNP not in BRCA1 GWAS SNP allocation on iCOGS chip.a: rs13387042 was previously found to be associated only under the 2-df model.b: analysis under a competing risks model.